Endolytix

Endolytix is developing therapeutics that can address antibiotic resistance problems. The prevalence of nontuberculous mycobacterial infections (NTMs) in the US alone is projected to increase 8.2% annually with a current inability to cure patients due to antibiotic resistance. This is further complicated by the fact that mycobacteria can hide within patients' macrophages making them less accessible. Endolytix is developing therapies that can effectively kill pathogenic NTM mycobacteria both inside and outside of macrophages. To kill the pathogens inside macrophages, Endolytix is building targeted drug delivery vehicles for their bactericidal payloads.

Jobs: